CLEC12A/MICL/CLL-1 Protein, Human, Recombinant (His), FITC-Labeled

CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML.

Pack Size	Availability	Price/USD
100 μg	5 days	$ 1,400.00
500 μg	5 days	$ 3,720.00
1 mg	5 days	$ 6,210.00

Pack Size

Availability

Price/USD

Quantity

100 μg

5 days

$ 1,400.00

500 μg

5 days

$ 3,720.00

1 mg

5 days

$ 6,210.00

Description

Species	Human
Expression System	HEK293
Tag	N-His
Accession Number	Q5QGZ9-2
Synonyms	DCAL-2, HECL, CLL-1, CLECSF7, CD371, CLEC12A, PRO34150, MICL, CLECSF11, CD303, DLEC, DCAL2, CLL1
Construction	Recombinant FITC-Labeled Human CLEC12A/MICL/CLL-1 Protein is expressed from HEK293 with His tag at the N-Terminus. It contains His65-Ala265.[Accession \|Q5QGZ9-2]
Protein Purity	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Molecular Weight	The protein has a predicted MW of 24.6 kDa. Due to glycosylation, the protein migrates to 35-55 kDa based on Tris-Bis PAGE result.

Endotoxin	Less than 1EU per μg by the LAL method.
Formulation	Supplied as 0.22μm filtered solution in PBS (pH 7.4).
Stability & Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Shipping	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Research Background	CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML.